|Bid||5.45 x 1200|
|Ask||5.58 x 2200|
|Day's Range||5.43 - 5.60|
|52 Week Range||3.51 - 7.66|
|Beta (3Y Monthly)||2.44|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 1, 2017 - Nov 6, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||15.17|
TherapeuticsMD Inc NASDAQ/NGS:TXMDView full report here! Summary * Bearish sentiment is high Bearish sentimentShort interest | NegativeShort interest is extremely high for TXMD with more than 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting TXMD. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold TXMD had net inflows of $937 million over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
TherapeuticsMD, Inc. (TXMD), an innovative, leading women’s healthcare company, today announced the schedule of oral presentations on clinical data for BIJUVATM (estradiol and progesterone capsules, 1 mg/100 mg) and ANNOVERATM (segesterone acetate/ethinyl estradiol vaginal system), and poster presentations related to menopause symptoms and treatments, at the International Society for the Study of Women’s Sexual Health (ISSWSH) and the International Society of Sexual Medicine (ISSM) joint annual meeting in Atlanta, GA on March 8-9, 2019. BIJUVA is the first and only FDA-approved bio-identical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate-to-severe vasomotor symptoms (commonly known as hot flashes or flushes) due to menopause in women with a uterus.
NEW YORK, March 05, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.
TherapeuticsMD, Inc. (TXMD), an innovative, leading women’s healthcare company, today announced that the company will participate in two upcoming healthcare conferences. Chief Executive Officer Robert G. Finizio will provide an overview of the company at the conferences.
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Feb. 21.) Eli Lilly And Co (NYSE: LLY ) Gossamer ...
On a per-share basis, the Boca Raton, Florida-based company said it had a loss of 17 cents. The results matched Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...
Successful Launch of IMVEXXY®, Strong PositiveTrends Continue for Prescriptions and Patient Refills
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! While small-cap stocks, such as TherapeuticsMD, Inc. (NASDAQ:TXMD) with itsRead More...
TherapeuticsMD, Inc. (TXMD), an innovative women’s healthcare company, today announced that it will report its fourth quarter and full year 2018 financial results on Thursday, February 21, 2019, after the closing of the U.S. financial markets. Following the announcement, executive management will host a conference call and webcast at 4:30 p.m. ET on such date to discuss the Company’s financial results and provide a business update.
Investors need to pay close attention to TherapeuticsMD (TXMD) stock based on the movements in the options market lately.
TherapeuticsMD, Inc. , an innovative women’s healthcare company, today announced that the company will participate in the 37th Annual J.P. Morgan Healthcare Conference.
In this daily bar chart of TXMD, below, we can see that prices are in a downtrend from June. The daily On-Balance-Volume (OBV) line shows a decline which indicates more aggressive selling, even at these low price levels. In this weekly bar chart of TXMD, we also have a weak picture.
On CNBC's "Mad Money Lightning Round" , Jim Cramer said Owens Corning (NYSE: OC ) is related to housing and it has been wrecked by the Fed. Mortgages rates went up too fast, said Cramer. Hormel ...
Jim Cramer races through his responses to callers' stock questions, including one on a group he's telling investors to buy right now.
Is TherapeuticsMD Inc (NASDAQ:TXMD) a good stock to buy right now? We at Insider Monkey like to examine what billionaires and hedge funds think of a company before doing days of research on it. Given their 2 and 20 payment structure, hedge funds have more resources than the average investor. The funds have access to […]